Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow UNITED THERAPEUTICS Corp

Get SEC filing alerts via email and in your feed for UNITED THERAPEUTICS Corp

UTHR

UNITED THERAPEUTICS Corp

About UNITED THERAPEUTICS Corp

United Therapeutics is a biotech company focused on developing therapies for pulmonary arterial hypertension and other life-threatening diseases. It markets inhaled, injectable, and oral medications, and is pioneering organ manufacturing, xenotransplantation, and regenerative medicine to address organ shortages. Its core value lies in innovative treatments, advanced organ technologies, and sustainable delivery solutions, serving global markets with a focus on rare and severe conditions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from UNITED THERAPEUTICS Corp

1
1
UNITED THERAPEUTICS Corp United Therapeutics Reports Q1 2026 Financial Results with $781.5M Revenue

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
UNITED THERAPEUTICS Corp United Therapeutics Reports $3.18 Billion Revenue, Driven by Tyvaso Sales

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
UNITED THERAPEUTICS Corp United Therapeutics Reports 7% Revenue Growth to $799.5 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
UNITED THERAPEUTICS Corp United Therapeutics Reports 12% Revenue Growth to $798.6 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
UNITED THERAPEUTICS Corp United Therapeutics Reports 17.2% Revenue Growth to $794.4 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
UNITED THERAPEUTICS Corp United Therapeutics Reports 23% Revenue Growth and Improved Net Income in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments